Progressive Left Ventricular Remodeling for Predicting Mortality in Children With Dilated Cardiomyopathy: The Pediatric Cardiomyopathy Registry

Abstract

Background Pediatric dilated cardiomyopathy often leads to death or cardiac transplantation. We sought to determine whether changes in left ventricular (LV) end‐diastolic dimension (LVEDD), LV end‐diastolic posterior wall thickness, and LV fractional shortening (LVFS) over time may help predict adverse outcomes. Methods and Results We studied children up to 18 years old with dilated cardiomyopathy, enrolled between 1990 and 2009 in the Pediatric Cardiomyopathy Registry. Changes in LVFS, LVEDD, LV end‐diastolic posterior wall thickness, and the LV end‐diastolic posterior wall thickness:LVEDD ratio between baseline and follow‐up echocardiograms acquired ≈1 year after diagnosis were determined for children who, at the 1‐year follow‐up had died, received a heart transplant, or were alive and transplant‐free. Within 1 year after diagnosis, 40 (5.0%) of the 794 eligible children had died, 117 (14.7%) had undergone cardiac transplantation, and 585 (73.7%) had survived without transplantation. At diagnosis, survivors had higher median LVFS and lower median LVEDD Z scores. Median LVFS and LVEDD Z scores improved among survivors ( Z score changes of +2.6 and −1.1, respectively) but remained stable or worsened in the other 2 groups. The LV end‐diastolic posterior wall thickness:LVEDD ratio increased in survivors only, suggesting beneficial reverse LV remodeling. The risk for death or cardiac transplantation up to 7 years later was lower when LVFS was improved at 1 year (hazard ratio [HR], 0.83; P =0.004) but was higher in those with progressive LV dilation (HR, 1.45; P <0.001). Conclusions Progressive deterioration in LV contractile function and increasing LV dilation are associated with both early and continuing mortality in children with dilated cardiomyopathy. Serial echocardiographic monitoring of these children is therefore indicated. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00005391.